IOP and Tolerability Study of Preserved Bimatoprost 0.1% or Tafluprost Unit Dose Preservative Free 15microgram/ml, in Patients With OHT or Glaucoma Suitable for Prostaglandin Therapy (SPORTII)

NCT02471105 Phase 4 UNKNOWN

This cross-over study will investigate the efficacy and safety of BIMMD and TUDPF in a clinical setting.

Details

Lead sponsor	Universitaire Ziekenhuizen KU Leuven
Phase	Phase 4
Status	UNKNOWN
Enrolment	67
Start date	2015-09
Completion	2017-12

Conditions

• Ocular Hypertension
• Glaucoma

Interventions

• Preserved Bimatoprost 0.01%
• Tafluprost Unit Dose Preservative Free 15microgram/ml

Primary outcomes

• the difference in mean IOP values between the 2 groups — 6 months

Countries

Austria, Belgium, Italy, Switzerland, United Kingdom